Extreme disruption of heterochromatin is required for accelerated hematopoietic aging.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
04 06 2020
Historique:
received: 22 08 2019
accepted: 22 03 2020
pubmed: 19 4 2020
medline: 10 2 2021
entrez: 19 4 2020
Statut: ppublish

Résumé

Loss of heterochromatin has been proposed as a universal mechanism of aging across different species and cell types. However, a comprehensive analysis of hematopoietic changes caused by heterochromatin loss is lacking. Moreover, there is conflict in the literature around the role of the major heterochromatic histone methyltransferase Suv39h1 in the aging process. Here, we use individual and dual deletion of Suv39h1 and Suv39h2 enzymes to examine the causal role of heterochromatin loss in hematopoietic cell development. Loss of neither Suv39h1 nor Suv39h2 individually had any effect on hematopoietic stem cell function or the development of mature lymphoid or myeloid lineages. However, deletion of both enzymes resulted in characteristic changes associated with aging such as reduced hematopoietic stem cell function, thymic involution and decreased lymphoid output with a skewing toward myeloid development, and increased memory T cells at the expense of naive T cells. These cellular changes were accompanied by molecular changes consistent with aging, including alterations in nuclear shape and increased nucleolar size. Together, our results indicate that the hematopoietic system has a remarkable tolerance for major disruptions in chromatin structure and reveal a role for Suv39h2 in depositing sufficient H3K9me3 to protect the entire hematopoietic system from changes associated with premature aging.

Identifiants

pubmed: 32305044
pii: S0006-4971(20)61977-2
doi: 10.1182/blood.2019002990
doi:

Substances chimiques

Heterochromatin 0
Repressor Proteins 0
Suv39h1 protein, mouse EC 2.1.1.
Methyltransferases EC 2.1.1.-
Histone-Lysine N-Methyltransferase EC 2.1.1.43
Suv39h2 protein, mouse EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2049-2058

Informations de copyright

© 2020 by The American Society of Hematology.

Auteurs

Christine R Keenan (CR)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; and.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

Nadia Iannarella (N)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; and.

Gaetano Naselli (G)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; and.

Naiara G Bediaga (NG)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; and.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

Timothy M Johanson (TM)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; and.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

Leonard C Harrison (LC)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; and.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

Rhys S Allan (RS)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; and.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH